Critical Contrast: Jushi (JUSHF) versus Its Peers

Jushi (OTCMKTS:JUSHFGet Free Report) is one of 53 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Jushi to similar companies based on the strength of its earnings, dividends, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Jushi and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jushi -24.16% -320.66% -10.31%
Jushi Competitors -48.57% -31.53% -7.91%

Volatility and Risk

Jushi has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, Jushi’s rivals have a beta of 1.32, suggesting that their average stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

21.7% of Jushi shares are owned by institutional investors. Comparatively, 16.2% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 21.0% of Jushi shares are owned by insiders. Comparatively, 22.5% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Jushi and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Jushi $269.45 million -$65.10 million -2.13
Jushi Competitors $326.19 million -$162.92 million -10.08

Jushi’s rivals have higher revenue, but lower earnings than Jushi. Jushi is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Jushi and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jushi 0 2 0 0 2.00
Jushi Competitors 246 546 909 66 2.45

As a group, “Medicinals & botanicals” companies have a potential upside of 75.86%. Given Jushi’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Jushi has less favorable growth aspects than its rivals.

Summary

Jushi rivals beat Jushi on 9 of the 13 factors compared.

About Jushi

(Get Free Report)

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of cannabis assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, Nevada, and Massachusetts. The company also offers hemp-based CBD products, including cannabis dry flower, vaporizer forms of cannabis, edibles, cannabis oil in capsules, tinctures, cannabis in topical products, and other cannabis products, as well as vape cartridges, disposables, and concentrates under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. In addition, it operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. The company is headquartered in Boca Raton, Florida.

Receive News & Ratings for Jushi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jushi and related companies with MarketBeat.com's FREE daily email newsletter.